Neonatal Screening 2026: What Changes in the Heel Prick Test and Who Must Act

Key data

Spain's neonatal screening system currently shows a gap of up to 22 diseases between autonomous communities: while the common NHS portfolio requires screening for 21 pathologies, some autonomous communities detect up to 43. A newborn in one region may receive early diagnosis of diseases that in another community are not detected until serious symptoms appear. The Law 3/2026, published on July 31, 2026, launches the legal mechanism to correct this inequality.

The regulation modifies the Law 16/2003 on cohesion and quality of the NHS and the Legislative Royal Decree 1/2015 on medicines, and imposes on the Ministry of Health an annual evaluation of the program with specific technical criteria.

What does this regulation establish?

Law 3/2026 introduces four blocks of specific changes:

The process of updating the Framework Document must include the participation of scientific societies and patient associations, which introduces a formal consultation mechanism that did not previously exist.

Economic and operational impact

For managers of regional health systems and hospitals, this law has direct operational consequences:

• Pressure to expand the screening portfolio: The gap between the 21 common diseases and the 43 already screened by some autonomous communities marks the expansion horizon. Communities with smaller portfolios will need to plan the progressive incorporation of new pathologies.
• New cost-effectiveness criteria: Any incorporation of a disease into the program must be justified with analysis of clinical effectiveness and cost-effectiveness, which implies investment in technical evaluation.
• Protocol updates: The protocols of the Interterritorial Council of the NHS (CISNS) must be reviewed to include requirements for response time, access to diagnosis and diagnostic confirmation.
• Professional training: Specific training actions in rare diseases are mandated, with the organizational and economic cost this implies for health services.
• Coordination with the pharmaceutical sector: The modification of Legislative Royal Decree 1/2015 on medicines may affect the availability and financing of treatments linked to diseases detected in screening.

Who does it affect?

• Ministry of Health: Obligated to conduct annual evaluation of the program and to update the Framework Document within 12 months.
• Autonomous communities: Must adapt their screening programs to the new CISNS protocols and to the criteria for timing, access and diagnostic confirmation.
• Hospitals and neonatology units: Review of internal procedures to comply with the new standards for timing and access.
• NHS healthcare professionals: Obligated to participate in training actions on rare diseases mandated by the law.
• Scientific societies and patient associations: Formally incorporated into the process of updating the Framework Document.
• Pharmaceutical industry: Affected by the modification of Legislative Royal Decree 1/2015 regarding medicines linked to rare diseases detected in screening.
• Families with newborns: Direct beneficiaries of the reduction of territorial inequalities in early diagnosis.

Practical example

An autonomous community that currently screens 21 diseases (the minimum of the common portfolio) compared to another that already reaches 43 must now plan its expansion roadmap under the new criteria formalized by Law 3/2026.

Before this law, that autonomous community could incorporate new pathologies without binding technical criteria. From now on, any expansion must be justified with analysis of clinical effectiveness, cost-effectiveness and ethical requirements, and must fit into the updated CISNS protocols with criteria for timing and access.

Additionally, neonatology professionals in that community must complete the training actions in rare diseases mandated by the law, which implies planning training schedules and allocating resources before the Ministry specifies the program in the coming 12 months.

What should healthcare organizations do now?

1. Audit the current screening portfolio: Identify how many diseases are screened in the community and the distance from the maximum of 43 already applied by other autonomous communities. This allows anticipating the impact of future mandatory expansions.
2. Review internal protocols for timing and access: The new CISNS criteria will include requirements for response time and diagnostic confirmation. It is advisable to anticipate whether current processes meet them.
3. Plan training in rare diseases: Identify which healthcare professionals must complete the training actions mandated and reserve budget and time for this before the program is specified.
4. Participate in the process of updating the Framework Document: Scientific societies and patient associations now have a formal channel for participation. Relevant organizations must activate their presence in this process in the coming 12 months.
5. Monitor the modification of RDL 1/2015: If the organization manages medicines linked to rare diseases detected in screening, review the impact of changes in Legislative Royal Decree 1/2015 on access and financing.
6. Monitor the Ministry's annual evaluation: From now on, the Ministry will publish annual evaluations of the program. Incorporate this schedule into the organization's regulatory monitoring.

Official source

Consult complete regulation in official source

Notice: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2026-16654